


RECEIVED

DEC 26 2001

PATENT

Customer No. 1600/2900

Attorney Docket No. 02481.1702



IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Application of:

**Bernward SCHÖLKENS et al.**

Application No.: 09/645,556

Filed: August 25, 2000

For: PHARMACEUTICAL  
FORMULATIONS AND USE  
THEREOF IN THE PREVENTION  
OF STROKE, DIABETES AND/OR  
CONGESTIVE HEART FAILURE

)  
)  
) Group Art Unit: 1615

) Examiner: M. Bahar  
)  
)

Assistant Commissioner for Patents  
Washington, DC 20231

Sir:

**Transmittal Letter**


Enclosed is a reply to the Office Action of June 20, 2001. The item(s) checked below are appropriate:

- ☒ Applicant(s) hereby petition(s) for a three month(s) extension of time to respond to the above Office Action. The fee of \$920.00 for the Extension is enclosed.
- ☒ A fee of \$180.00 to cover the accompanying Supplemental Information Disclosure Statement is enclosed.
- ☒ check for \$1100.00 to cover the above fee(s) is enclosed.

Please grant any extensions of time required to enter this response and charge any additional required fees to our deposit account 06-0916.

Dated: December 20, 2001

By:

  
Steven J. Scott  
Reg. No. 43,911

#9 RECEIVED

DEC 26 2001

TECH CENTER 1600/2900  
PATENT

Customer No. 22,852

Attorney Docket No. 02481.1702-00



IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Application of: )  
)  
**Bernward SCHÖLKENS et al.** ) Group Art Unit: 1615  
)  
Application No.: 09/645,556 ) Examiner: M. Bahar  
)  
Filed: August 25, 2000 )  
)  
For: PHARMACEUTICAL )  
FORMULATIONS AND USE )  
THEREOF IN THE PREVENTION )  
OF STROKE, DIABETES AND/OR )  
CONGESTIVE HEART FAILURE )

Assistant Commissioner for Patents  
Washington, DC 20231

Sir:

**THIRD SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT  
UNDER 37 C.F.R. § 1.97(c)**

Pursuant to 37 C.F.R. §§ 1.56 and 1.97(c), Applicants bring to the attention of the Examiner the documents listed on the attached PTO 1449. This Information Disclosure Statement is being filed after the events in Section 1.97(b), but before the mailing date of either a Final action, Quayle action, or a Notice of Allowance. Under the provisions of 37 C.F.R. § 1.97(c), this Information Disclosure Statement is accompanied by a fee of \$180.00.

Copies of the listed documents are attached.

Applicants respectfully request that the Examiner consider the listed documents and indicate that they were considered by making appropriate notations on the attached form.

This submission does not represent that a search has been made or that no better art exists and does not constitute an admission that each or all of the listed documents are material or constitute "prior art." If the Examiner applies any of the documents as prior art against any claim in the application and Applicants determine that the cited documents do not constitute "prior art" under United States law,

Applicants reserve the right to present to the office the relevant facts and law regarding the appropriate status of such documents.

Applicants further reserve the right to take appropriate action to establish the patentability of the disclosed invention over the listed documents, should one or more of the documents be applied against the claims of the present application.

If there is any fee due in connection with the filing of this Statement, please charge the fee to our Deposit Account No. 06-0916.

Respectfully submitted,

FINNEGAN, HENDERSON, FARABOW,  
GARRETT & DUNNER, L.L.P.

Dated: December 20, 2001

By: 

Steven J. Scott  
Reg. No. 43,911